NCT06519760 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
| NCT ID | NCT06519760 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Carbonic Anhydrase IX |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-07-30 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-07-30 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 68Ga-C1 in PET/CT imaging in clear cell renal cell carcinoma patients. It will also learn about the safety, tolerability and radiation dosimetry of 68Ga-C1. Researchers will compare the diagnostic value of 68Ga-C1 PET/CT and 18F-FDG PET/CT in Chinese patients with indeterminate renal masses or confirmed clear cell renal cell carcinoma.
Eligibility Criteria
Inclusion Criteria: 1. Signed written informed consent； 2. Age ≥18； 3. Patients with confirmed or suspected clear cell renal cell carcinoma; 4. Expected survival ≥6 months. Exclusion Criteria: 1. Renal mass is known to be a metastasis of another primary tumor; 2. Have other malignancies that require treatment; 3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks; 4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²; 5. Pregnant and lactating women or female patients plan to become pregnant within 6 months; 6. Uncontrolled psychiatric disorders; 7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).
Contact & Investigator
Kan Gong
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT06519760 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Carbonic Anhydrase IX. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06519760 currently recruiting?
Yes, NCT06519760 is actively recruiting participants. Contact the research team at kan.gong@bjmu.edu.cn for enrollment information.
Where is the NCT06519760 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06519760 clinical trial?
NCT06519760 is sponsored by Peking University First Hospital. The principal investigator is Kan Gong at Peking University First Hospital. The trial plans to enroll 200 participants.